Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.

BMC neurology - 9 Jan 2020

Wattmo Carina, Blennow Kaj, Hansson Oskar

Abstract excerpt

BACKGROUND: We investigated the potential associations between cerebro-spinal fluid (CSF) levels of phosphorylated tau (P-tau) and total tau (T-tau) with short-term response to cholinesterase inhibitor (ChEI) treatment, longitudinal outcome and progression rates in Alzheimer's disease (AD). METHODS: This prospective, observational study included 129 participants clinically diagnosed with mild-to-moderate AD, who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activities of Daily Living
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoprotein E4

Share to Biomarkers

Share to Cholinesterase Inhibitors

Share to Disease Progression

Share to Phosphorylation

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 31918679
DOI: 10.1186/s12883-019-1591-0
PMCID: PMC6951013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.PMID 31918679Read ↗

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.Semantic proximity Read ↗

CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.Semantic proximity Read ↗

Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseasesSemantic proximity Read ↗

CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's DiseaseSemantic proximity Read ↗

The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer’s DiseaseSemantic proximity Read ↗

Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adultsSemantic proximity Read ↗

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.Semantic proximity Read ↗

Phosphorylated Tau-Aβ42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer’s Disease in Multiplex Immunoassay Panels of Cerebrospinal FluidSemantic proximity Read ↗

Timing of changes in Alzheimer’s disease plasma biomarkers as assessed by amyloid and tau PET clocksSemantic proximity Read ↗

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?Semantic proximity Read ↗

Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent InsightsSemantic proximity Read ↗

Amyloid-beta and tau proteins as biochemical markers of Alzheimer's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.